Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Serum concentrations of tissue polypeptide antigen in patients with vulvarintraepithelial neoplasia and vulvar cancer
Autore:
Hefler, L; Tempfer, C; Frischmuth, K; Maenner, G; Concin, N; Sliutz, G; Reinthaller, A; Leodolter, S; Kainz, C;
Indirizzi:
Univ Vienna, Sch Med, Dept Obstet & Gynecol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 stet & Gynecol, A-1090 Vienna, Austria Univ Vienna, Sch Med, Dept Med Lab Diagnost, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 d Lab Diagnost, A-1090 Vienna, Austria Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 tet & Gynecol, Houston, TX 77030 USA
Titolo Testata:
TUMOR BIOLOGY
fascicolo: 2, volume: 21, anno: 2000,
pagine: 98 - 104
SICI:
1010-4283(200003/04)21:2<98:SCOTPA>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
SQUAMOUS-CELL-CARCINOMA; HUMAN CHORIONIC-GONADOTROPIN; TUMOR-MARKERS; CARCINOEMBRYONIC ANTIGEN; CERVICAL-CANCER; PROGNOSTIC-SIGNIFICANCE; LUNG-CANCER; MULTIVARIATE-ANALYSIS; COLORECTAL-CANCER; TPA;
Keywords:
tumor marker; cytokeratin; tissue polypeptide antigen; vulvar cancer; vulvar intraepithelial neoplasia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Hefler, L Univ Vienna, Sch Med, Dept Obstet & Gynecol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 ustria
Citazione:
L. Hefler et al., "Serum concentrations of tissue polypeptide antigen in patients with vulvarintraepithelial neoplasia and vulvar cancer", TUMOR BIOL, 21(2), 2000, pp. 98-104

Abstract

The aim of the present study was to evaluate the clinical usefulness of the cytokeratin tumor marker tissue polypeptide antigen (TPA) in patients with vulvar cancer. This retrospective study comprises 41 patients with vulvarcancer FIGO stages I-III, 17 patients with vulvar intraepithelial neoplasia (VIN) III, and 40 healthy female controls. Serum concentrations of TPA were measured using a microparticle enzyme immunoassay. Results were correlated to clinical data. Median serum concentrations of TPA in healthy female controls, patients with VIN ill, and patients with vulvar cancer were 42 U/I(range 12-192), 53 U/I (range 17-127.9) and 57 U/I (range 4.2-423), respectively (Mann-Whitney U test, p = 0.8). Serum concentrations of TPA were notassociated with stage of disease, histological grade, and age at the time of diagnosis. In vulvar cancer patients, elevated serum concentrations of TPA prior to therapy were not associated with a shortened disease-free or overall survival (log-rank test: p = 0.5 and p = 0.9, respectively). In a multivariate Cox regression model comprising tumor stage and TPA, tumor stage,but not TPA revealed a statistically significant influence on disease-free(Cox proportional hazard regression model, p = 0.05 and p = 0.6, respectively) and overall (Cox proportional hazard regression model, p = 0.04 and p = 0.8, respectively) survival of patients with vulvar cancer. We conclude that cytokeratin expression, as reflected by serum concentrations of TPA, does not play a role in the natural history of vulvar cancer. The evaluation of serum concentrations of TPA prior to therapy is not recommended. Copyright (C) 2000 S. Karger AG, Basel.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 12:42:58